Functional precision medicine aims to identify effective treatments for patients without targetable mutations. Current research in oncology screens patient-derived models of cancer using endpoint assays. However, these assays fail to capture dynamic responses and tumor heterogeneity. We developed multiparametric quantitative phase imaging (mQPI), a labelfree technique, to screen single cells in real-time. Our work shows mQPI correlates with endpoint assays in measuring drug response in cells from patient derived xenograft organoids (PDxOs), while also capturing time of response and singlecell heterogeneity. Additionally, we demonstrate that mQPI can differentiate organoids that come from the same patient, but which originated from different sites.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.